|
|
|
|
| LEADER |
04389nam a22005415i 4500 |
| 001 |
978-3-030-16624-3 |
| 003 |
DE-He213 |
| 005 |
20210621173928.0 |
| 007 |
cr nn 008mamaa |
| 008 |
190604s2019 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783030166243
|9 978-3-030-16624-3
|
| 024 |
7 |
|
|a 10.1007/978-3-030-16624-3
|2 doi
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Cancer Stem Cell Resistance to Targeted Therapy
|h [electronic resource] /
|c edited by Cristina Maccalli, Matilde Todaro, Soldano Ferrone.
|
| 250 |
|
|
|a 1st ed. 2019.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2019.
|
| 300 |
|
|
|a XIX, 256 p. 21 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 19
|
| 505 |
0 |
|
|a Cancer Stem Cells: from birth to death -- A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies -- Cancer Stem Cells in Lung Cancer: Roots of Drug Resistance and Targets for Novel Therapeutic Strategies -- Overexpression of YY1 Regulates the Resistance of Cancer Stem Cells: Targeting YY1 -- Cancer Stem Cell Challenges in Melanoma Characterization and Treatment -- Harnessing the immune system to target cancer cells -- Targeting leukemia stem cells and the immunological bone marrow microenvironment -- Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy -- Cancer stem cells: the players of immune evasion from immunotherapy -- Index.
|
| 520 |
|
|
|a This book represents an updated summary of the state of the art of the characterization of cancer stem cell/cancer initiating cell (CSC/CIC) properties. Experts provide an overview of the definition and biological properties of CSCs/CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies. It also discusses limitations in the achievement of a definitive biological characterization of CSCs/CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs/CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells. This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs/CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs/CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
1 |
4 |
|a Cancer Research.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B11001
|
| 650 |
2 |
4 |
|a Immunology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B14000
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B1700X
|
| 700 |
1 |
|
|a Maccalli, Cristina.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 700 |
1 |
|
|a Todaro, Matilde.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 700 |
1 |
|
|a Ferrone, Soldano.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer Nature eBook
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030166236
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030166250
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030166267
|
| 830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 19
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-16624-3
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 912 |
|
|
|a ZDB-2-SXB
|
| 950 |
|
|
|a Biomedical and Life Sciences (SpringerNature-11642)
|
| 950 |
|
|
|a Biomedical and Life Sciences (R0) (SpringerNature-43708)
|
